KUKimberly Uchida

Kimberly Uchida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kimberly Uchida has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glycocalyx biomarkers as early predictors of endotheliopathy in pediatric and young adult hematopoietic stem cell transplantation patients

    by Kimberly Uchida, Kris M Mahadeo, Jennifer McArthur, Yvonne Avent, Chia-Wei Hsu, Haitao Pan, Lama Elbahlawan, Melissa Hines, Akshay Sharma, Ruth G. Tatevossian, et al.

    Introduction: Discovery of biomarkers predictive of endotheliopathy after hematopoietic stem cell transplant (HSCT) has the potential to more rapidly identify vulnerable patients, guide treatment decisions, track responses to therapy, and inform targets for novel treatment. This study aimed to evaluate the levels and predictive capabilities of glycocalyx biomarkers for endotheliopathy in the first 100 days following HSCT in pediatric and young adult patients. Methods: Parallel prospective observational pilot studies were performed to examine markers related to endothelial glycocalyx structure, function, and regulation at St. Jude Children’s Research Hospital (SJCRH) and MD Anderson Cancer Center (MDACC). The MDACC study took a discovery-driven approach using a 55-biomarker panel performed at two early timepoints whereas the SJCRH study adopted a targeted approach evaluating a 6-biomarker panel at eight scheduled timepoints. Biomarker levels in patients’ post-HSCT who did or did not develop endotheliopathy were compared at specific timepoints predicative value was assessed using Area Under the Curve (AUC) and Youden Index. Results: In the SJCRH study, Syndecan-1 and Angiopoietin-2 levels were found to be significantly different between cases of endotheliopathy and controls at multiple time points. Predictive values for both were good to excellent when comparing the time-point immediately before diagnosis of endotheliopathy in cases to standardized time-points of Days 7, 14, and 21 in controls. This was noted for endotheliopathy in general as well for sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) or transplant-associated thrombotic microangiopathy (TA-TMA). In the MDACC study, a signature of markers was found to be associated with endotheliopathy on Days 0 and 7. Specifically, Tissue inhibitor of metalloproteinases-1 (TIMP-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) had perfect performance (AUC of 1) for endotheliopathy. Discussion: Biomarkers of glycocalyx damage and dysregulation have significant potential to predict endotheliopathy in pediatric and young adult patients undergoing HSCT. The convergence of these two studies, one targeted and one unbiased, affirms the central role of endothelial injury in post-HSCT complications and provides a list of potential candidate predictors. Given small sample size and hence limited generalizability, further research is required to validate these findings in larger patient cohorts.


  • Open Access

    Elevation of NT-proBNP Levels in Pediatric and Young Adult Hematopoietic Stem Cell Transplant Patients with Endotheliopathy

    by Kimberly Uchida, Xiaomeng Yuan, Jennifer McArthur, Rebekah Lassiter, Haitao Pan, Dinesh Keerthi, Katherine Tsai, Yvonne Avent, Melissa Hines, Hugo R. Martinez, et al.

    Background/Objectives: Hematopoietic stem cell transplantation (HSCT) in pediatric and young adult (YA) patients can lead to endotheliopathy, such as thrombotic microangiopathy (TMA), sinusoidal obstruction syndrome (SOS), and diffuse alveolar hemorrhage (DAH). Natriuretic peptides have been studied as markers of endotheliopathy and critical illness. We hypothesized that an elevation in NT-proBNP was associated with the development of endotheliopathy (DAH, SOS, or TMA) in the first 100 days following HSCT in pediatric and YA patients. Methods: IRB-exempt status was obtained. This retrospective case–control study reviewed HSCT at our institution from 2016 to 2020. Cases were selected based on an endotheliopathy diagnosis in the first 100 days after HSCT. Cases were matched with controls. Baseline and near-event NT-proBNP levels were compared between cases and matched controls. The effect of NT-proBNP levels on developing endotheliopathy was estimated using conditional logistic regression. Results: Sixty-two patients were included (31 cases, 31 controls). Near-event NT-proBNP was significantly higher in cases compared to controls (median: 473 vs. 187 pg/mL, p = 0.03, Wilcoxon rank–sum test), in contrast to comparison in baseline NT-proBNP (median: 86 vs. 86 pg/mL, p = 0.51). After adjusting for covariates, an association between near-event NT-proBNP and odds of developing endotheliopathy did not achieve statistical significance. However, trends from most common transplant indications suggested an association between an elevated near-event NT-proBNP level and endotheliopathy, particularly in acute lymphoblastic leukemia (ALL) patients. Conclusions: NT-proBNP should be studied further as a biomarker for endotheliopathy in pediatric and YA patients undergoing HSCT. This may be particularly relevant for patients undergoing HSCT for ALL.

  • Open Access

    NT-proBNP as a Biomarker of Endotheliopathy in Pediatric and Young Adult Hematopoietic Stem Cell Transplantation

    by Kimberly Uchida, Xiaomeng Yuan, Jennifer McArthur, Rebekah Lassiter, Haitao Pan, Dinesh Keerthi, Katherine Tsai, Yvonne Avent, Melissa Hines, Hugo R. Martinez, et al.

    Background/Objectives: Hematopoietic stem cell transplantation (HSCT) in pediatric and young adult (YA) patients can lead to endotheliopathy, such as thrombotic microangiopathy (TMA), sinusoidal obstruction syndrome (SOS), and diffuse alveolar hemorrhage (DAH). Natriuretic peptides have been studied as markers of endotheliopathy and critical illness. We hypothesized that elevation in NT-proBNP was associated with development of endotheliopathy (DAH, SOS, or TMA) in the first 100 days following HSCT in pediatric and YA patients. Methods: IRB exempt status was obtained. This retrospective case-control study reviewed HSCT at our institution from 2016-2020. Cases were selected based on an endotheliopathy diagnosis in the first 100 days after HSCT. Cases were matched with controls. Baseline and near-event NT-proBNP levels were compared between cases and matched controls. Effect of NT-proBNP levels on developing endotheliopathy was estimated using conditional logistic regression. Results: Sixty-two patients were included (31 cases, 31 controls). Near-event NT-proBNP was significantly higher in cases compared to controls (Median: 473 vs. 187 pg/mL, p = 0.03, Wilcoxon rank-sum test), in contrast to comparison in baseline NT-proBNP (Median: 86 vs. 86 pg/mL, p = 0.51). After adjusting for co-variates, association between near-event NT-proBNP and odds of developing endotheliopathy did not achieve statistical significance. However, trends from most common transplant indications suggested an association between elevated near-event NT-proBNP level and endotheliopathy, particularly in acute lymphoblastic leukemia (ALL) patients. Conclusions: NT-proBNP should be studied further as a biomarker for endotheliopathy in pediatric and YA patients undergoing HSCT. This may be particularly relevant for patients undergoing HSCT for ALL.